Essential role of NMDA receptor channel ε4 subunit (GluN2D) in the effects of hencyclidine, but not methamphetamine

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Hagino, Yoko ^a   Kasai, Shinya ^a   Han, Wenhua ^a   Yamamoto, Hideko ^a   Nabeshima, Toshitaka ^b   Mishina, Masayoshi ^c   Ikeda, Kazutaka ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; PHENCYCLIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; IN VIVO STUDY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; ANIMAL; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

MUS;

ANIMALS; CORPUS STRIATUM; DOPAMINE; LOCOMOTION; METHAMPHETAMINE; MICE; MICE, KNOCKOUT; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 78149418887     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013722     Document Type: Article

References (67)

1. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
2. Sturgeon RD, Fessler RG, Meltzer HY (1979) Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 59: 169-179.
3. Castellani S, Adams PM (1981) Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 73: 143-154.
4. Nabeshima T, Fukaya H, Yamaguchi K, Ishikawa K, Furukawa H, et al. (1987) Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur J Pharmacol 135: 23-33.
5. Xu X, Domino EF (1994) Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav 47: 603-608.
6. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79: 565-575.
7. Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 11: 81-86.
8. Kemp JA, Foster AC, Wong EHF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 10: 294-298.
9. Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26: 1435-1439.
10. Snell LD, Yi SJ, Johnson KM (1988) Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol 145: 223-226.
11. Garey RE, Heath RG (1976) The effects of phencyclidine on the uptake of 3Hcatecholamines by rat striatal and hypothalamic synaptosomes. Life Sci 18: 1105-1110.
12. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25: 192-216.
13. Robinson TE, Becker JB (1986) Enduring changes in brain and behaviorproduced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396: 157-198.
14. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33: 639-677.
15. Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208: 203-209.
16. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D (2001) Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors,transporters, and synaptic vesicle stores. J Neurosci 21: 5916-5924.
17. Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60: 527-535.
18. Benwell ME, Balfour DJ, Lucchi HM (1993) Influence of tetrodotoxin and calcium on changes in extracellular dopamine levels evoked by systemic nicotine. Psychopharmacology (Berl) 112: 467-474.
19. Parker EM, Cubeddu LX (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J Pharmacol Exp Ther 245: 199-210.
20. Heikkila RE, Orlansky H, Cohen G (1975) Studies on the distinction between uptake inhibition and release of [3H]dopamine in rat brain tissue slices. Biochem Pharmacol 24: 847-852.
21. Horn AS, Coyle JT, Snyder SH (1971) Catecholamine uptake by synaptosomes from rat brain: structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol 7: 66-80.
22. Green AL (1971) Inhibition of rat and mouse brain monoamine oxidases by (+)-amphetamine. Biochem J 121: 37P-38P.
23. Green AL, el Hait MA (1978) Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo. J Pharm Pharmacol 30: 262-263.
24. Miller HH, Shore PA, Clarke DE (1980) In vivo monoamine oxidase inhibitionby d-amphetamine. Biochem Pharmacol 29: 1347-1354.
25. Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179: 4-29.
26. Watanabe M, Inoue Y, Sakimura K, Mishina M (1992) Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 3: 1138-1140.
27. Ikeda K, Nagasawa M, Mori H, Araki K, Sakimura K, et al. (1992) Cloning and expression of the e4 subunit of the NMDA receptor channel. FEBS Lett 313: 34-38.
28. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, et al. (1992) Molecular diversity of the NMDA receptor channel. Nature 358: 36-41.
29. Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T, et al. (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357: 70-74.
30. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, et al. (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256: 1217-1221.
31. Mori H, Mishina M (2003) Roles of diverse glutamate receptors in brain functions elucidated by subunit-specific and region-specific gene targeting. Life Sci 74: 329-336.
32. Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M (1993) Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 4: 687-690.
33. Ikeda K, Araki K, Takayama C, Inoue Y, Yagi T, et al. (1995) Reduced spontaneous activity of mice defective in the e4 subunit of the NMDA receptor channel. Brain Res Mol Brain Res 33: 61-71.
34. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, et al. (2001) Hyperfunction of dopaminergic and serotonergic neuronal systems in micelacking the NMDA receptor e1 subunit. J Neurosci 21: 750-757.
35. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, et al. (2002) Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor e4 subunit. J Neurosci 22: 2335-2342.
36. Boyce-Rustay JM, Holmes A (2006) Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31: 2405-2414.
37. Kadotani H, Hirano T, Masugi M, Nakamura K, Nakao K, et al. (1996) Motordiscoordination results from combined gene disruption of the NMDA receptorNR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit. J Neurosci 16: 7859-7867.
38. Ebralidze AK, Rossi DJ, Tonegawa S, Slater NT (1996) Modification of NMDA receptor channels and synaptic transmission by targeted disruption of the NR2C gene. J Neurosci 16: 5014-5025.
39. Sprengel R, Suchanek B, Amico C, Brusa R, Burnashev N, et al. (1998) Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. Cell 92: 279-289.
40. Kutsuwada T, Sakimura K, Manabe T, Takayama C, Katakura N, et al. (1996) Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor e2 subunit mutant mice. Neuron 16: 333-344.
41. Li Y, Erzurumlu RS, Chen C, Jhaveri S, Tonegawa S (1994) Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 76: 427-437.
42. Forrest D, Yuzaki M, Soares HD, Ng L, Luk DC, et al. (1994) Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 13: 325-338.
43. Troupin AS, Mendius, JR, Cheng, F, Risinger, MW (1986) MK-801. In: Meldrum BS, Porter RJ, eds. New anticonvulsant drugs (series title: Currentproblems in epilepsy, vol 4). London: Libbey. pp 191-201.
44. Chapman CD, Gazzara RA, Howard SG (1990) Effects of phencyclidine on extracellular levels of dopamine, dihydroxyphenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 29: 319-325.
45. Lillrank SM, O'Connor WT, Saransaari P, Ungerstedt U (1994) In vivo effects of local and systemic phencyclidine on the extracellular levels of catecholamines and transmitter amino acids in the dorsolateral striatum of anaesthetized rats. Acta Physiol Scand 150: 109-115.
46. Nishijima K, Kashiwa A, Hashimoto A, Iwama H, Umino A, et al. (1996) Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse 22: 304-312.
47. Hondo H, Yonezawa Y, Nakahara T, Nakamura K, Hirano M, et al. (1994) Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 633: 337-342.
48. Hertel P, Mathe JM, Nomikos GG, Iurlo M, Mathe AA, et al. (1995) Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 72: 103-114.
49. Adams B, Moghaddam B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
50. Miyamoto Y, Yamada K, Nagai T, Mori H, Mishina M, et al. (2004) Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor e1 subunit. Eur J Neurosci 19: 151-158.
51. Ohmori T, Abekawa T, Muraki A, Koyama T (1994) Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol Biochem Behav 48: 587-591.
52. Wolf ME, Khansa MR (1991) Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res 562: 164-168.
53. Wolf ME, Jeziorski M (1993) Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization. Brain Res 613: 291-294.
54. Kuribara H, Asami T, Ida I, Iijima Y, Tadokoro S (1992) Effects of repeated MK-801 on ambulation in mice and in sensitization following methamphetamine. Psychopharmacology (Berl) 108: 271-275.
55. Carlsson A, Waters N, Waters S, Carlsson ML (2000) Network interactions in schizophrenia: therapeutic implications. Brain Res Brain Res Rev 31: 342-349.
56. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
57. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81: 363-369.
58. Mouri A, Noda Y, Enomoto T, Nabeshima T (2007) Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 51: 173-184.
59. Geyer MA, Ellenbroek B (2003) Animal behavior models of the mechanismsunderlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071-1079.
60. Lindahl JS, Keifer J (2004) Glutamate receptor subunits are altered in forebrain and cerebellum in rats chronically exposed to the NMDA receptor antagonist phencyclidine. Neuropsychopharmacology 29: 2065-2073.
61. Millan MJ (2005) N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 179: 30-53.
62. Makino C, Shibata H, Ninomiya H, Tashiro N, Fukumaki Y (2005) Identification of single-nucleotide polymorphisms in the human N-methyl-Daspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr Genet 15: 215-221.
63. Standaert DG, Testa CM, Young AB, Penney JB, Jr. (1994) Organization of Nmethyl- D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 343: 1-16.
64. Jones S, Gibb AJ (2005) Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J Physiol 569: 209-221.
65. Sakimura K, Kutsuwada T, Ito I, Manabe T, Takayama C, et al. (1995) Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor e1 subunit. Nature 373: 151-155.
66. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
67. Masuo Y, Matsumoto Y, Morita S, Noguchi J (1997) A novel method for counting spontaneous motor activity in the rat. Brain Res Brain Res Protoc 1: 321-326.